Mesenchymal stromal cell therapy in COPD: from bench to bedside

Area of Science:

• Pulmonology
• Regenerative Medicine
• Cell Therapy

Background:

• Chronic obstructive pulmonary disease (COPD) is a leading cause of death, with cigarette smoke as the primary risk factor.
• Smoking cessation is crucial, but persistent inflammation, apoptosis, and oxidative stress contribute to COPD progression.
• Current COPD therapies reduce symptoms but do not halt disease progression or mortality.

Purpose of the Study:

• To review recent preclinical studies on mesenchymal stromal cell (MSC) therapy for COPD and emphysema.
• To discuss the clinical application and outcomes of MSC treatment in COPD patients.

Main Methods:

• Review of preclinical research on MSC therapy for lung disorders, including emphysema.
• Analysis of clinical trial data where MSCs were used as an adjuvant therapy for COPD.

Main Results:

• Preclinical studies show encouraging outcomes for MSC therapy in emphysema models.
• Clinical trials indicate MSCs have a beneficial adjuvant role, improving pulmonary function and quality of life when combined with primary treatments.
• Combined therapies involving MSCs led to reduced systemic inflammation markers.

Conclusions:

• Mesenchymal stromal cell therapy holds potential for managing COPD, particularly as an adjunct to established treatments.
• Further research is needed to optimize MSC therapy for improved COPD patient outcomes.
• MSCs show promise in reducing inflammation and improving lung function in COPD patients when used alongside other therapies.